Datavault AI Inc. (NASDAQ: DVLT) has announced a SaaS agreement with Wellgistics Health Inc. (NASDAQ: WGRX) to co-develop PharmacyChain, a blockchain-enabled smart contract system aimed at optimizing prescription distribution from manufacturers to patients. The partnership leverages Datavault AI's patented Information Data Exchange platform to create secure, token-driven data transfers that enhance transparency and efficiency in pharmaceutical logistics.
According to the press release, the collaboration will build digital twins of logistics, delivery systems, and patients, supporting personalized health recommendations and creating new revenue streams in the $639 billion prescription drug market. CEO Nathaniel Bradley emphasized that the initiative will utilize blockchain technology to ensure data integrity and streamline the supply chain.
The PharmacyChain system is designed to address inefficiencies in the current pharmaceutical supply chain, where lack of transparency can lead to errors and delays. By implementing smart contracts, the system automates verification and transfer of data between stakeholders, reducing the potential for fraud and improving tracking of prescription drugs from manufacturing to patient delivery.
Datavault AI's Information Data Exchange platform enables digital twins by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. This capability is critical for creating accurate digital representations of the logistics network, which can be used for simulation, monitoring, and optimization.
Wellgistics Health, a healthcare technology company, brings expertise in pharmacy services and distribution. The partnership combines Datavault's AI and blockchain capabilities with Wellgistics' industry knowledge to develop a solution that could set a new standard for prescription drug logistics.
This development is significant as it applies blockchain technology to a high-value sector with complex supply chain challenges. The pharmaceutical industry has been exploring blockchain for drug traceability, especially with the Drug Supply Chain Security Act (DSCSA) in the United States requiring enhanced tracking. If successful, PharmacyChain could improve patient safety, reduce costs, and enable new business models such as tokenized incentives for adherence.
For more information, the full press release is available at https://ibn.fm/4hm51. Investors can find the latest news and updates about Datavault AI at https://ibn.fm/DVLT.
